Starpharma’s DEP® Irinotecan Demonstrates Superior Anti-tumour Activity

  • Jun 29, 2020 AEST
  • Team Kalkine

Starpharma Holdings Limited (ASX:SPL) disclosed that DEP® irinotecan in combination with anti PD-1 antibody (an immuno-oncology therapy) showed superior anti-tumour activity as well as significant survival benefit as compared to the immuno-oncology therapy alone in two colorectal cancer models.

SPL’s proprietary SN-38 nanoparticle, DEP® irinotecan currently is in Phase 2 clinical study, and these data in the colorectal cancer models provide crucial information for assisting with the identification of value-adding clinical combinations along with partnering opportunities.

On 29 June 2020, SPL quoted at A$1.175 up by 0.858% at AEST 11:50 AM.


The website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


Want to get exclusive insights into the star stock of the year? Gold stocks stood solid and ensured a safety net for investors.

Click now to access our report on Gold Stocks to understand how the rise in gold prices propelled the ASX-listed gold stocks, and many emerged as the star performer of the year.

Inside this report, you shall discover

How the price trends of gold have got it where it is With the rallying gold prices and the record-buying from Central Banks, the gold spot rose from $1,655.14 (low in December 2018) to $2,322.26 (high in August 2019). A promising return of over 40 percent was seen in the year 2019. Get exclusive insights into how the trends set the foundation for the performance and how Gold stocks seem to be a safe bet when you look back.

Which stocks you should have been looking at: Find out which stocks delivered promising returns to investors. Gold stocks such as Gold Road Resources Limited (ASX: GOR), Kirkland Lake Limited (ASX: KLA) Newcrest Mining Limited (ASX: NCM) delivered better returns against the S&P Commodity Producers Gold Total Return Index.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK